P3 Health Partners Inc (PIII)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$9.35+2.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Intact: The reason to own it still holds.
P3 Health Partners aims to grow revenue to $1.5B-$1.7B in 2026. Adjusted EBITDA is targeted at $40M for the year. The company showed revenue growth from $345M in 2025-Q3 to $386M in 2026-Q1. Recent earnings beat and contract wins support a business turnaround.
The company remains loss-making with negative EPS and free cash flow. Legal issues and delisting risks weigh on confidence. Revenue growth and profitability targets may not be sustained amid volatile management and sector risks.
The market reflects a sharp recent selloff and high risk due to losses and regulatory concerns. There is no clear consensus on revenue growth or earnings recovery, leaving uncertainty on the turnaround's durability.
Breaks if: Adjusted EBITDA remains below $20 million in FY26
Breaks if: Net loss worsens beyond -$110 million in FY25 or FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has a volatile management track record, but recent financial results have shown strength, keeping the thesis intact for now.
The market seems to be pricing in a high level of risk given the company's loss-making status and recent volatility. There is an expectation for continued revenue growth and improved adjusted EBITDA, but any negative guidance could lead to a significant credibility hit.
Management is focused on increasing revenue to $1.5B-$1.7B and raising adjusted EBITDA to $40M in 2026, with recent results showing some progress. However, the company has faced challenges with Nasdaq compliance, indicating ongoing risks that could impact fundamentals.
The thesis hinges on the company's ability to maintain momentum in the healthcare sector, especially if larger competitors continue to perform well. Additionally, any negative shifts in guidance or economic conditions, such as a weakening jobs report, could adversely affect the company's outlook.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: Receipt of new delisting notices or failure to meet listing standards
Breaks if: Total revenue falls below $1.4 billion in FY26
Grow total revenues to between $1.5 billion and $1.7 billion for the full year 2026.
Stated as a priority in 3 of last 3 quarters. Revenue grew modestly from $373.2M in 2025-Q1 to $386.4M in 2026-Q1. Management raised full-year 2026 revenue guidance from $1.5B-$1.7B at 2025-Q4 to $1.5B-$1.6B at 2026-Q2. The trajectory shows steady revenue growth and consistent guidance updates aligned with this priority.
“We raised our full-year 2026 total revenues guidance to $1,500 to $1,600 million.”
“Full-year 2026 total revenues guidance is $1,500 to $1,650 million.”
“Full-year 2026 total revenues guidance was $1,500 to $1,700 million.”
Over the next 1 to 3 years, PIII's performance will depend on its ability to navigate regulatory challenges and sustain growth in a volatile environment. Not investment advice.